Sograzepide
Sograzepide (Netazepide) is a potent, selective, and orally bioavailable gastrin/CCK-B receptor antagonist. It suppresses gastrin-mediated signaling and pappalysin 2 expression, demonstrating the ability to induce regression of type 1 gastric neuroendocrine tumors (gNETs) in clinical research. This small molecule is a valuable tool for investigating gastrin biology and gNET pathogenesis in both in vitro and in vivo models.
Product Specifications
CAS Number
155488-25-8
Product Name Alternative
Sograzepide, YM 220, YF476, YF-476, YF 476, YM220, YM-220, Netazepide, Gastrin, Gastrin/CCK-A, Gastrin/CCK-B
Field of Research
Pharmacology & Drug Discovery
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (6.62 mM) ; DMSO:80 mg/mL (160.46 mM)
Smiles
C (C (C (C) (C) C) =O) N1C=2C (C (=N[C@@H] (NC (NC3=CC (NC) =CC=C3) =O) C1=O) C4=CC=CC=N4) =CC=CC2
Molecular Formula
C28H30N6O3
Molecular Weight
498.58
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
SET, NT (SET, Protein SET, HLA-DR-associated protein II, Inhibitor of granzyme A-activated DNase, PHAPII, Phosphatase 2A inhibitor I2PP2A, Template-activating factor I) (Biotin)
SET, NT (SET, Protein SET, HLA-DR-associated protein II, Inhibitor of granzyme A-activated DNase, PHAPII, Phosphatase 2A inhibitor I2PP2A, Template-activating factor I) (Biotin)